参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Public Health Agency of Canada,Statistics Canada,Canadian Cancer Society,et al.Release notice - Canadian Cancer Statistics 2019.Avis de publication - Statistiques canadiennes sur le cancer 2019[J].Health Promot Chronic Dis Prev Can,2019,39(8-9):255.[3]Sidorenkov G,Stadhouders R,Jacobs C,et al.Multi-source data approach for personalized outcome prediction in lung cancer screening:update from the NELSON trial[J].Eur J Epidemiol,2023,38(4):445-454.[4]Henschke CI,Yip R,Shaham D,et al.The Regimen of Computed Tomography Screening for Lung Cancer:Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program[J].J Thorac Imaging,2021,36(1):6-23.[5]De Koning HJ,van der Aalst CM,de Jong PA,et al.Reduced lung-cancer mortality with volume CT screening in a randomized trial[J].N Engl J Med,2020,382:503-513.[6]Pastorino U,Silva M,Sestini S,et al.Prolonged lung cancer screening reduced 10-year mortality in the MILD trial:new confirmation of lung cancer screening efficacy[J].Ann Oncol,2019,30(10):1672.[7]Li N,Tan F,Chen W,et al.One-off low-dose CT for lung cancer screening in China:a multicentre,population-based,prospective cohort study[J].Lancet Respir Med,2022,10(4):378-391.[8]Ettinger DS,Wood DE,Aisner DL,et al.Non-Small Cell Lung Cancer,Version 3.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(5):497-530.[9]梁文华,黎才琛,何建行.肺癌早筛早诊的精准化探索[J].中国肿瘤临床,2021,48(10):506-510.[10]Li C,Liang H,Zhong N,et al.Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography:A Population Level Analysis[J].Thorac Oncol,2019,14(4):e82-e84.[11]中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2022版)[J].中华肿瘤杂志,2022,44(6):457-490.[12]Koo HJ,Choi CM,Park S,et al.Chest radiography surveillance for lung cancer:Results from a National Health Insurance database in South Korea[J].Lung Cancer,2019,128:120-126.[13]屠娜娜.低剂量CT扫描与普通剂量扫描诊断早期肺癌的效果比较[J].医学信息,2021,34(9):112-114,118.[14]Mazzone PJ,Silvestri GA,Souter LH,et al.Screening for Lung Cancer:CHEST Guideline and Expert Panel Report[J].Chest,2021,160(5):e427-e494.[15]Bartlett EC,Silva M,Callister ME,et al.False-Negative Results in Lung Cancer Screening-Evidence and Controversies[J].J Thorac Oncol,2021,16(6):912-921.[16]Lu H,Mu W,Balagurunathan Y,et al.Multi-window CT based radiomic signatures in differentiating indolent versus aggressive lung cancers in the National Lung Screening Trial:a retrospective study[J].Cancer Imaging,2019,19(1):45.[17]Wang Y,Wu B,Zhang N,et al.Research progress of computer aided diagnosis system for pulmonary nodules in CT images[J].J Xray Sci Technol,2020,28(1):1-16.[18]Ardila D,Kiraly AP,Bharadwaj S,et al.End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography[J].Nat Med,2019,25(6):954-961.[19]Liu J,Yuan S,Wang L,et al.Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer:A Systematic Review and Meta-Analysis[J].Biomed Res Int,2019,2019:8534761.[20]Machado Medeiros T,Altmayer S,Watte G,et al.18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer:a systematic review and meta-analysis[J].Eur Radiol,2020,30(7):3641-3649.[21]Ohno Y,Ozawa Y,Koyama H,et al.State of the Art MR Imaging for Lung Cancer TNM Stage Evaluation[J].Cancers (Basel),2023,15(3):950.[22]Zhu J,Li W,Zhou J,et al.The diagnostic value of narrow-band imaging for early and invasive lung cancer:a meta-analysis[J].Clinics (Sao Paulo),2017,72(7):438-448.[23]Bae S,Lim S,Ahn JJ,et al.Diagnosing peripheral lung lesions using endobronchial ultrasonography with guide sheath:A prospective registry study to assess the effect of virtual bronchoscopic navigation using a computed tomography workstation[J].Medicine (Baltimore),2020,99(17):e19870.[24]Haince JF,Joubert P,Bach H,et al.Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer:From the Genome to the Metabolome[J].Int J Mol Sci,2022,23(3):1215.[25]Benbassat J.Duration of lead time in screening for lung cancer[J].BMC Pulm Med,2021,21(1):4.[26]Lemieux ME,Reveles XT,Rebeles J,et al.Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning[J].Respir Res,2023,24(1):23.[27]Yadav S,Kashaninejad N,Masud MK,et al.Autoantibodies as diagnostic and prognostic cancer biomarker:Detection techniques and approaches[J].Biosens Bioelectron,2019,139:111315.[28]Sullivan FM,Mair FS,Anderson W,et al.Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging[J].Eur Respir J,2021,57(1):2000670.[29]Massion PP,Healey GF,Peek LJ,et al.Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer[J].J Thorac Oncol,2017,12(3):578-584.[30]Schlander M,Richardson J.QALYs In Health Resource Usage Decisions[J].Health Aff (Millwood),2022,41(4):609-610.[31]Criss SD,de Koning HJ,Plevritis SK,et al.Cost-Effectiveness Analysis of Lung Cancer Screening in the United States[J].Ann Intern Med,2020,172(10):706-707.[32]Yang S,Liu T,Liang G.The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi-omics data[J].Mol Oncol,2020,14(9):2069-2080.[33]Cressman S,Peacock SJ,Tammem?覿gi MC,et al.The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency[J].J Thorac Oncol,2017,12(8):1210-1222.
相似文献/References:
[1]尤 静.肺癌患者外周血CEA、NSE、CYFRA21-1联合检测的意义[J].医学信息,2018,31(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Journal of Medical Information,2018,31(13):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]戴 芳,曹晓美,王莉娜.肺癌患者疾病不确定感的影响因素与干预措施研究现状[J].医学信息,2018,31(08):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
DAI Fang,CAO Xiao-mei,WANG Li-na.Research Status on Influencing Factors and Intervention Measures of Disease Uncertainty in Patients with Lung Cancer[J].Journal of Medical Information,2018,31(13):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
[3]吴 倩,王一非.中西医结合治疗肺癌脑转移疗效与安全性的Meta分析[J].医学信息,2022,35(10):120.[doi:10.3969/j.issn.1006-1959.2022.10.029]
WU Qian,WANG Yi-fei.Meta-analysis of Efficacy and Safety of Integrated Traditional Chinese and Western Medicine in the Treatment of Brain Metastasis of Lung Cancer[J].Journal of Medical Information,2022,35(13):120.[doi:10.3969/j.issn.1006-1959.2022.10.029]
[4]王晓军.以时间护理为基础的呼吸训练与排痰管理对肺癌手术患者康复的影响研究[J].医学信息,2022,35(11):180.[doi:10.3969/j.issn.1006-1959.2022.11.048]
WANG Xiao-jun.Effect of Respiratory Training and Expectoration Management Based on Time Nursing on Rehabilitation of Patients with Lung Cancer Surgery[J].Journal of Medical Information,2022,35(13):180.[doi:10.3969/j.issn.1006-1959.2022.11.048]
[5]邢益辉,刘 曼,厉玛倩倩,等.快速康复对肺癌手术患者并发症发生及生活质量的影响研究[J].医学信息,2018,31(16):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
XING Yi-hui,LIU Man,LIMA Qian-qian,et al.Effect of Rapid Rehabilitation on Complications and Quality of Life in Patients with Lung Cancer Surgery[J].Journal of Medical Information,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
[6]朱晓晓,张 顺,蔡 挺.镍暴露相关的肺癌发生分子机制研究[J].医学信息,2018,31(17):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
ZHU Xiao-xiao,ZHANG Shun,CAI Ting.Molecular Mechanism of Lung Cancer Related to Nickel Exposure[J].Journal of Medical Information,2018,31(13):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
[7]付云杰.肺癌患者血浆D-二聚体、NSE及CYFRA21-1联合检测的临床价值[J].医学信息,2018,31(23):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
FU Yun-jie.Clinical Value of the Plasma D-dimer and Serum NSE,CYFRA21-1 Combined Detection in the Diagnosis of Lung Cancer[J].Journal of Medical Information,2018,31(13):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
[8]覃柳麻,何慧敏.2014~2016年广西肿瘤医院肺癌患者流行病学及病理分布特征分析[J].医学信息,2019,32(05):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
QIN Liu-ma,HE Hui-min.Epidemiological and Pathological Distribution Characteristics of Lung Cancer Patients in Guangxi Cancer Hospital from 2014 to 2016[J].Journal of Medical Information,2019,32(13):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
[9]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,32(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Journal of Medical Information,2019,32(13):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
[10]杨寿林,宋庆志,吴路发,等.肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析[J].医学信息,2019,32(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Journal of Medical Information,2019,32(13):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]